| RESEARCH AREA | Social analysis of biomedical innovations, life and health | Education and public engagement with science and technology | History, philosophy, and sociology of science | Policy, political economy and governance of science and technology |
| NAME OF PROJECT | Social Pharmaceutical Innovation for Unmet Medical Needs (SPIN) (Douglas 2020-2023) | STS Undergraduate program development (2020-present Pavri, Lazenby, Monaldi, Douglas, Lungu) | Mountains, Romanticism and the origins of the biosphere/critical zone (Hamm) | Social Pharmaceutical Innovation for Unmet Medical Needs (SPIN) (Douglas 2020-2023) |
| Sensors, Senses and Sensibility: An Ethnographic Study of ‘Control’ in Type 1 Diabetes (Mialet) | Transition pedagogy module development for first year students (2020-present) Pavri and Domenikos | Women in the History of Quantum Physics: Laura Chalk and the Stark Effect (Monaldi) | Informing Future Orphan Drug Coverage Using Scenario Studies (iFOCUSS) (Douglas 2015-2018) | |
| Kinds of Evidence in the Assessment of Biofield Healing Modalities (Lazenby) | From Information Exchange to Technological Innovation: The Early Apple Macintosh User Groups (Lungu, 2015 – present) | Synthetic Biology for Human Health: Ethical, Legal and Social Issues (SYBHEL) (Douglas 2013-2015) | ||
Informing Future Orphan Drug Coverage Using Scenario Studies (iFOCUSS) (Douglas 2015-2018) | ||||
| KEY PUBLICATIONS | ||||
| Mialet, H. (2022). Bodies in Balance: Tracking Type 1 Diabetes. Body & Society, 28(3), 89-113. | Elwick, J. (2022) Making a Grade: Victorian Examinations and the Rise of Standardized Testing. University of Toronto Press. | Monaldi, D. (2022). The evolving understanding of quantum statistics, in O. Freire et al. (Eds.), The Oxford Handbook of the History of Quantum Interpretations, (pp. 255-275). Oxford University Press. | Douglas, C. M. (2023). International Experiences and Made-in-Canada “Social Pharmaceutical Innovations” as Responses to Challenges Facing Drugs for Rare Diseases. Healthcarepapers, 21(1), 66-72. | |
Douglas, C. M., Aith, F., Boon, W., de Neiva Borba, M., Doganova, L., Grunebaum, S., … & Kleinhout-Vliek, T. (2022). Social pharmaceutical innovation and alternative forms of research, development and deployment for drugs for rare diseases. Orphanet Journal of Rare Diseases, 17(1), 1-13. | Douglas, C. M., Wilcox, E., Burgess, M., & Lynd, L. D. (2015). Why orphan drug coverage reimbursement decision-making needs patient and public involvement. Health Policy, 119(5), 588-596. | Mialet, H. (2019) “The Distributed Centered Subject,” in Jill Bennett (ed.), Thinking in The World (London: Bloomsbury), 131-149. | Douglas, C. M., Panagiotoglou, D., Dragojlovic, N., & Lynd, L. (2021). Methodology for constructing scenarios for health policy research: The case of coverage decision-making for drugs for rare diseases in Canada. Technological Forecasting and Social Change, 171, 120960. | |
Mialet, H. (2020). How dogs become accurate instruments: care, attunement, and reflexivity. Humanities and Social Sciences Communications, 7(1), 1-9. | Lungu, D. and Stachniak, Z. (2011). Following TRACE: The Computer Hobby Movement in Canada. Scientia Canadensis, 34(1), 1-23. | Monaldi, D. (2019). The statistical style of reasoning and the invention of Bose‐Einstein Statistics. Berichte Zur Wissenschaftsgeschichte, 42(4), 307-337. | Boeckhout, M., & Douglas, C. M. (2015). Governing the research-care divide in clinical biobanking: Dutch perspectives. Life sciences, society and policy, 11(1), 1-16. | |
Mialet, H. (2019) “Becoming the Other: The Body in Translation,” in David Gruber and Lynda Walsh (eds.), The Routledge Handbook of Language & Science (Abingdon and New York: Routledge), 375-384. | Monaldi, D. (2017). Fritz London and the scale of quantum mechanisms. Studies in History and Philosophy of Modern Physics 60, 35-45. | Douglas, C. M., & Stemerding, D. (2014). Challenges for the European governance of synthetic biology for human health. Life Sciences, Society and Policy, 10(1), 1-18. | ||
Douglas, C. M. (2016). Bio-objectification of clinical research patients: impacts on the stabilization of new medical technologies. In Vermeulen, N., Tamminen, S., & Webster, A. (Eds.). Bio-objects: life in the 21st century (pp. 59-67). Ashgate. | Hamm, E. (2012). Mining History: People, Knowledge, Power. Earth Sciences History, 31. | Douglas, C. M., & Stemerding, D. (2013). Governing synthetic biology for global health through responsible research and innovation. Systems and Synthetic Biology, 7, 139-150. | ||
Webster, A., Douglas, C., & Lewis, G. (2009). Making sense of medicines: ‘lay pharmacology’ and narratives of safety and efficacy. Science as Culture, 18(2), 233-247. | Hamm, E. (2012). Improving Mennonites in an Age of Revolution. The Conrad Grebel Review, 30(1): 24-51. | |||
Mialet, H. (2012) “Where STS Would Be Without Latour? What Would Be Missing?” Social Studies of Science, 42/3: 456-461. |
Home » Research Projects & Outputs